ALK and lung carcinoma: Particularly, this study showed that: (a) the analysis of BRAF, EGFR, KRAS, PI3KCA mutations, ALK fusions and FGFR1 amplifications is clinically relevant and helps to define tumor subgroups that can take benefit from patient individualized therapies; thus, the EGFR-mutant lung cancers can be subdivided into two different subgroups according to the presence (poorer prognosis) or absence (better prognosis) of TP53 mutations; TP53-mutant tumors can be subdivided into two subgroups, one with RB1 no loss (with a better prognosis) and the other one with RB1 loss (with a poorer prognosis) [86].